Skip to content
Screener

Aclaris Therapeutics ACRS Single Reportable — Operating Income

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Operating Income
-$98.41M+3.1%
Capricor Therapeutics logo
CAPRSingle Reportable — Operating Income
-$36.77M-47.2%
LQD
LQDASingle Reportable — Operating Income
$61.5M+274%
Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Operating Income
-$54.12M-17.7%
El Pollo Loco logo
LOCOSingle Reportable — Operating Income
$18.68M+65.3%
Onto Innovation logo
ONTOSingle Reportable — Operating Income
$33.23M-29.0%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
(In thousands)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other research and development(2)1,3981,4623,2972,962
Total research and development18,06611,44933,72323,033
General and administrative(3)6,0485,38612,79111,525
Licensing1,2351,3352,6282,345
Revaluation of contingent consideration3001,5003001,800
Segment operating loss$(24,238)$(18,408)$(46,430)$(36,492)
Other income2,7332,9795,1015,978
Segment loss before income taxes$(21,505)$(15,429)$(41,329)$(30,514)

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's single reportable — operating income?
Aclaris Therapeutics (ACRS) reported single reportable — operating income of -$24.24M in Q2 2026.
How has Aclaris Therapeutics's single reportable — operating income changed year-over-year?
Aclaris Therapeutics's single reportable — operating income decreased by 31.7% year-over-year, from -$18.41M to -$24.24M.
What does single reportable — operating income mean?
Calculated as the segment's total revenue minus its operating expenses, including research, development, and administrative costs. This metric represents the core profitability of the segment's business operations before interest and taxes. It is the primary measure of the segment's ability to generate sustainable value from its activities.

Ask your AI about Aclaris Therapeutics's single reportable — operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude